Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ola Ghaith, Mustapha El-Halabi, Jana G Hashash & Ala I Sharara. (2010) Investigational agents for the irritable bowel syndrome. Expert Opinion on Investigational Drugs 19:10, pages 1161-1178.
Read now
Read now
John T Bassett & Brooks D Cash. (2008) A review of irritable bowel syndrome and an update on therapeutic approaches. Expert Opinion on Pharmacotherapy 9:7, pages 1129-1143.
Read now
Read now
Peter Layer, Jutta Keller, Helena Loeffler & Andreas Kreiss. (2007) Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Therapeutics and Clinical Risk Management 3:1, pages 107-118.
Read now
Read now
Sylvie Bradesi, Kirsten Tillisch & Emeran Mayer. (2006) Emerging drugs for irritable bowel syndrome. Expert Opinion on Emerging Drugs 11:2, pages 293-313.
Read now
Read now
Articles from other publishers (42)
Annie Londregan, Tyler D. Alexander, Manuel Covarrubias & Scott A. Waldman. (2023) Fundamental Neurochemistry Review: The role of enteroendocrine cells in visceral pain. Journal of Neurochemistry.
Crossref
Crossref
Ishtiaque Ahammad, Zeshan Mahmud Chowdhury, Arittra Bhattacharjee, Sheikh Sunzid Ahmed, Farzana Akter, Mohammad Uzzal Hossain, Keshob Chandra Das, Chaman Ara Keya & Md. Salimullah. (2023) Structure-based pharmacological screening, molecular docking and dynamic simulation reveals Dexketoprofen as a repurposable drug against Alzheimer's disease. Informatics in Medicine Unlocked 43, pages 101380.
Crossref
Crossref
Albert Orock, Tian Yuan & Beverley Greenwood-Van Meerveld. (2021) Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance. Frontiers in Pain Research 1.
Crossref
Crossref
Ji Yeon Chung, Jae-Ho Jeong & Juhyun Song. (2020) Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota. Frontiers in Aging Neuroscience 12.
Crossref
Crossref
Alexander Roberts, Gillian Grafton, Andrew D. Powell, Kristian Brock, Chunlin Chen, Dejian Xie, Jinkun Huang, Shuang Liu, Alison J. Cooper, Catherine A. Brady, Omar Qureshi, Zania Stamataki, David D. Manning, Nicholas A. Moore, Bruce J. Sargent, Peter R. Guzzo & Nicholas M. Barnes. (2020)
CSTI-300 (SMP-100); a Novel 5-HT
3
Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome
. Journal of Pharmacology and Experimental Therapeutics 373:1, pages 122-134.
Crossref
Crossref
Fei Chen, Sheng-Qiang Lai, Fei-Fei Zhu, Qiang Meng, Yu Jiang, Wei Yu & Bing Han. (2018)
Cu-Catalyzed Radical Cascade Annulations of Alkyne-Tethered
N
-Alkoxyamides with Air: Facile Access to Isoxazolidine/1,2-Oxazinane-Fused Isoquinolin-1(2
H
)-ones
. ACS Catalysis 8:9, pages 8925-8931.
Crossref
Crossref
G. E. Boeckxstaens & M. M. Wouters. (2017) Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome. Neurogastroenterology & Motility 29:6, pages e13007.
Crossref
Crossref
Monika Gaba & Chander Mohan. (2015) Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Medicinal Chemistry Research 25:2, pages 173-210.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
343
347
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
162
163
.
Michael D. Gershon. (2013) 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Current Opinion in Endocrinology, Diabetes & Obesity 20:1, pages 14-21.
Crossref
Crossref
Nicholas A. Moore, Bruce J. Sargent, David D. Manning & Peter R. Guzzo. (2012)
Partial Agonism of 5-HT
3
Receptors: A Novel Approach to the Symptomatic Treatment of IBS-D
. ACS Chemical Neuroscience 4:1, pages 43-47.
Crossref
Crossref
Magdy El-Salhy, Doris Gundersen, Jan Gunnar Hatlebakk & Trygve Hausken. (2012) Irritable bowel syndrome: treatment options. Clinical Practice 9:5, pages 591-600.
Crossref
Crossref
Susan Lucak. (2012) Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron. Therapeutic Advances in Gastroenterology 5:4, pages 215-218.
Crossref
Crossref
Philip M. Brown, Douglas A. Drossman, Alastair J.J. Wood, Gary A. Cline, Kenny S. Frazier, Jessica I. Jackson, Johanna Bronner, Joel Freiman, Brian Zambrowicz, Arthur Sands & Michael D. Gershon. (2011) The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome. Gastroenterology 141:2, pages 507-516.
Crossref
Crossref
James H. Lewis. (2011) The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies. Drug Safety 34:7, pages 545-565.
Crossref
Crossref
A. J. LEMBO, F. CREMONINI, N. MEYERS & R. HICKLING. (2010) Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation – a double‐blind, randomized, placebo‐controlled, study. Alimentary Pharmacology & Therapeutics 31:9, pages 979-990.
Crossref
Crossref
Evelin Painsipp, Anaid Shahbazian & Peter Holzer. (2009) Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. British Journal of Pharmacology 158:5, pages 1210-1226.
Crossref
Crossref
J. M. JARCHO, L. CHANG, S. M. BERMAN, B. SUYENOBU, B. D. NALIBOFF, M. D. LIEBERMAN, V. Z. AMEEN, M. A. MANDELKERN & E. A. MAYER. (2008)
Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT
3
receptor antagonist: a pilot study
. Alimentary Pharmacology & Therapeutics 28:3, pages 344-352.
Crossref
Crossref
D. T. Beattie & J. A. M. Smith. (2008) Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn-Schmiedeberg's Archives of Pharmacology 377:3, pages 181-203.
Crossref
Crossref
J. H. De Maeyer, R. A. Lefebvre & J. A. J. Schuurkes. (2008) 5-HT4 receptor agonists: similar but not the same. Neurogastroenterology & Motility 20:2, pages 99-112.
Crossref
Crossref
Christopher W Hammerle & Christina M Surawicz. (2008) Updates on treatment of irritable bowel syndrome. World Journal of Gastroenterology 14:17, pages 2639.
Crossref
Crossref
d. grundy, p. mclean & r. stead. (2007) Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat. Neurogastroenterology & Motility 19:7, pages 607-616.
Crossref
Crossref
Sylvie Bradesi, Lijun Lao, Peter G. McLean, Wendy J. Winchester, Kevin Lee, Gareth A. Hicks & Emeran A. Mayer. (2007) Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia ☆. Pain 130:1, pages 56-65.
Crossref
Crossref
m. camilleri. (2007)
Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT
3
antagonist treatment?
. Neurogastroenterology & Motility 19:2, pages 77-84.
Crossref
Crossref
Lucinda A Harris & Lin Chang. (2016) Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome. Women's Health 3:1, pages 15-27.
Crossref
Crossref
l. bueno, f. de ponti, m. fried, g. a. kullak-ublick, m. a. kwiatek, d. pohl, e. m. m. quigley, j. tack & n. j. talley. (2007) Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterology & Motility 19:s1, pages 89-119.
Crossref
Crossref
Michael D. Gershon & Jan Tack. (2007) The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. Gastroenterology 132:1, pages 397-414.
Crossref
Crossref
S. Dar & H.R. Dalton. 2007.
371
382
.
S. Evangelista. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
597
601
.
Evan S. Dellon & Yehuda Ringel. (2006) Treatment of functional diarrhea. Current Treatment Options in Gastroenterology 9:4, pages 331-342.
Crossref
Crossref
Lucinda A. Harris, Stephanie Hansel, John DiBaise & Michael D. Crowell. (2006) Irritable bowel syndrome and chronic constipation: Emerging drugs, devices, and surgical treatments. Current Gastroenterology Reports 8:4, pages 282-290.
Crossref
Crossref
William D. Chey & Brooks D. Cash. (2006) Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment. Current Gastroenterology Reports 8:4, pages 273-281.
Crossref
Crossref
Cesare Gridelli. (2006) Antiemetic therapy in older cancer patients. Aging Health 2:3, pages 449-459.
Crossref
Crossref
Lucinda A Harris & Lin Chang. (2006) Irritable bowel syndrome: new and emerging therapies. Current Opinion in Internal Medicine 5:3, pages 297-304.
Crossref
Crossref
Michael Camilleri, Lionel Bueno, Fabrizio de Ponti, Jean Fioramonti, R. Bruce Lydiard & Jan Tack. (2006) Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 130:5, pages 1421-1434.
Crossref
Crossref
Michel Delvaux & Gérard Gay. (2006) Approche du malade avec une diarrhée fonctionnelle. Gastroentérologie Clinique et Biologique 30:3, pages 415-420.
Crossref
Crossref
Eamonn MM Quigley. (2006) Changing face of irritable bowel syndrome. World Journal of Gastroenterology 12:1, pages 1.
Crossref
Crossref
B. D. CASH & W. D. CHEY. (2005) Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Alimentary Pharmacology and Therapeutics 22:11-12, pages 1047-1060.
Crossref
Crossref
Timothy J Ness. (2005) Pelvic pain in women and men: recent findings. Current Opinion in Anaesthesiology 18:5, pages 555-562.
Crossref
Crossref
Eamonn MM Quigley. (2005) Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. Nature Clinical Practice Gastroenterology & Hepatology 2:10, pages 436-437.
Crossref
Crossref
Michael Camilleri. (2005) Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics 6:5, pages 491-501.
Crossref
Crossref